Text Size

Vascular Sensitivity to Adrenergic Agonists in Patients With CHF and in Healthy Subjects

The recruitment status of this study is unknown because the information has not been verified recently.
Verified October 2008 by Hadassah Medical Organization.
Recruitment status was  Active, not recruiting
Sponsor:
Information provided by:
Hadassah Medical Organization
ClinicalTrials.gov Identifier:
NCT00782782
First received: October 26, 2008
Last updated: October 28, 2008
Last verified: October 2008
History of Changes
  Purpose

Congestive Heart failure (CHF) is asociated with changes in cardiac function and vascular responses. The aim of this study is to characterize these differences. Our hypothesis is, that there are differences in vascular responses between healthy subjects and patients with CHF.


Condition
Congestive Heart Failure

Study Type: Observational
Study Design: Observational Model: Case Control
Time Perspective: Prospective
Official Title: Effect of Medications on Vascular Response in Patients With CHF and in Healthy Subjects

Resource links provided by NLM:

MedlinePlus related topics: Heart Failure
U.S. FDA Resources

Further study details as provided by Hadassah Medical Organization:

Primary Outcome Measures:
  • vascular sensitivity (ED50) and response (Emax) to dexmedetomidine, phenylephrine, isoproterenol and terbutaline [ Time Frame: 3 weeks ] [ Designated as safety issue: No ]

Biospecimen Retention:   Samples Without DNA

samples for norepinephrine and PRA will be retained


Estimated Enrollment: 80
Study Start Date: August 2008
Estimated Study Completion Date: December 2011
Estimated Primary Completion Date: December 2009 (Final data collection date for primary outcome measure)
  Eligibility

Ages Eligible for Study:   18 Years to 70 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population

Patients with congestive heart failure NYHA I-II and healthy subjects

Criteria

Inclusion Criteria:

  • Patients with congestive heart failure NYHA I-II
  • Stable clinical condition

Exclusion Criteria:

  • Resting systolic blood pressure < 100
  • Resting heart rate < 50
  • Hypersensitivity to dexmedetomidine, phenylephrine, isoproterenol, terbutaline
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00782782

Locations
Israel
Hadassah University Hospital
Jerusalem, Israel, 92110
Sponsors and Collaborators
Hadassah Medical Organization
Investigators
Principal Investigator: Mordechai Muszkat Hadassah University Hospital
  More Information

No publications provided

Responsible Party: Mordechai Muszkat, Hadassah University Hospital
ClinicalTrials.gov Identifier: NCT00782782     History of Changes
Other Study ID Numbers: 366-28.12.07
Study First Received: October 26, 2008
Last Updated: October 28, 2008
Health Authority: Israel: Ministry of Health

Additional relevant MeSH terms:
Heart Failure
Heart Diseases
Cardiovascular Diseases
Adrenergic Agonists
Adrenergic Agents
 Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Physiological Effects of Drugs

ClinicalTrials.gov processed this record on June 17, 2013